Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Reo Vaccine is a veterinary biologic developed by Middle East for Vaccines (MEVAC) to protect poultry against avian reovirus infections. Avian reovirus is a significant pathogen in the poultry industry, causing conditions such as viral arthritis, tenosynovitis, malabsorption syndrome, and immunosuppression, which lead to substantial economic losses. The vaccine works by stimulating the bird's immune system to develop specific antibodies and cellular immunity against the virus. This protective immune response helps prevent clinical disease and reduces viral shedding within vaccinated flocks. MEVAC, an American-Egyptian animal health company established in 2011, produces this vaccine as part of its extensive portfolio of poultry immunization solutions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Reo Vaccine.